(Carolyn Kaster / AP)

Members of the Trump administration got together on Sunday to talk about President Trump's plan to repeal and replace Obamacare — but a photo tweeted by White House chief of staff Reince Priebus doesn't show any Treasury Department officials at the table, despite the likelihood that the plan will involve big tax changes.

At the table were many members of the president's health care and policy teams, including Department of Health and Human Services Secretary Tom Price, yet-to-be confirmed Centers for Medicare and Medicaid Services head Seema Verma, and White House aide Stephen Miller.

But no one from the Treasury Department was there, and a source who heard about the snub from a White House economic adviser said the department feels shut out of the process. A White House spokesperson responded that while Treasury Secretary Steven Mnuchin "wasn't in attendance at this particular meeting, he is absolutely involved in the discussion of how best to repeal and replace Obamacare."

How weird is this? The person who relayed this conversation to me put it this way: "There's always tension between health policy folks and economic policy folks in any administration, but this is an entirely different level."

Why Treasury is hugely important to the health reform debate: It's Treasury's job to make and implement tax policy, and a key part of the emerging GOP replacement plan is a tax credit, which would be administered by Treasury. The GOP plan also is likely to include a cap on the tax break for employer-sponsored coverage benefits, which is also Treasury's jurisdiction. So it'd be problematic for the administration to make policy on either of these items without Treasury.

Why this matters: Health policy is enormously complicated to write and then actually implement. Thus, major players need to be working together every step of the way to avoid any potentially devastating consequences of badly written or badly implemented policy.

Go deeper

Updated 19 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 11:30 p.m. ET: 31,478,387 — Total deaths: 968,726 Total recoveries: 21,622,862Map.
  2. U.S.: Total confirmed cases as of 11:30 p.m. ET: 6,895,685 — Total deaths: 200,768 — Total recoveries: 2,646,959 — Total tests: 96,612,436Map.
  3. Health: The U.S. reaches 200,000 coronavirus deaths — The CDC's crumbling reputation — America turns against coronavirus vaccine.
  4. Politics: Elected officials are failing us on much-needed stimulus.
  5. Business: Two-thirds of business leaders think pandemic will lead to permanent changes — Fed chair warns economy will feel the weight of expired stimulus.
  6. Sports: NFL fines maskless coaches.

Trump pushes to expand ban against anti-racism training to federal contractors

Trump speaking at Moon Township, Penns., on Sept. 22. Photo: Mandel Ngan/AFP via Getty Images

President Trump announced late Tuesday that the White House attempt to halt federal agencies' anti-racism training would be expanded to block federal contractors from "promoting radical ideologies that divide Americans by race or sex."

Why it matters: The executive order appears to give the government the ability to cancel contracts if anti-racist or diversity trainings focused on sexual identity or gender are organized. The memo applies to executive departments and agencies, the U.S. military, federal contractors and federal grant recipients.

Dan Primack, author of Pro Rata
4 hours ago - Economy & Business

GoodRx prices IPO at $33 per share, valued at $12.7 billion

Illustration: Sarah Grillo/Axios

GoodRx, a price comparison app for prescription drugs at local pharmacies, on Tuesday night raised $1.14 billion in its IPO, Axios has learned.

By the numbers: GoodRx priced its shares at $33 a piece, above its $24-$28 per share offering range, which will give it an initial market cap of around $12.7 billion.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!